Background: The roles of soluble epoxide hydrolase and lipid mediators in inflammatory and neuropathic pain could be relevant in laminitis pain management. Objectives: To determine soluble epoxide hydrolase (sEH) activity in the digital laminae, sEH inhibitor potency in vitro, and efficacy of a sEH inhibitor as an adjunct analgesic therapy in chronic laminitic horses. Study design: In vitro experiments and clinical case series. Methods: sEH activity was measured in digital laminae from euthanised healthy and laminitic horses (n = 5-6/group). Potency of 7 synthetic sEH inhibitors was determined in vitro using equine liver cytosol. One of them (t-TUCB; 0.1 mg/kg bwt i.v. every 24 h) was selected based on potency and stability, and used as adjunct therapy in 10 horses with severe chronic laminitis (Obel grades 2, one horse; 3-4, nine horses). Daily assessments of forelimb lifts, pain scores, physiologic and laboratory examinations were performed before (baseline) and during t-TUCB treatment. Data are presented as mean AE s.d. and 95% confidence intervals (CI). Results: sEH activity in the digital laminae from laminitic horses (0.9AE0.6 nmol/min/mg; 95% CI 0.16-1.55 nmol/min/mg) was significantly greater (P = 0.01) than in healthy horses (0.17AE0.09 nmol/min/mg; CI 0.07-0.26 nmol/min/mg). t-TUCB as an adjunct analgesic up to 10 days (4.3AE3 days) in laminitic horses was associated with significant reduction in forelimb lifts (36AE22%; 95% CI 9-64%) and in pain scores (18AE23%; 95% CI 2-35%) compared with baseline (P = 0.04). One horse developed gas colic and another corneal vascularisation in a blind eye during treatment. No other significant changes were observed. Main limitations: Absence of control group and evaluator blinding in case series. Conclusions: sEH activity is significantly higher in the digital laminae of actively laminitic compared with healthy horses, and use of a potent inhibitor of equine sEH as adjunct analgesic therapy appears to decrease signs of pathologic pain in laminitic horses.
Introduction
Equine laminitis is a complex, extremely painful and disabling condition [1] . It is associated with local inflammation, up-regulation of proinflammatory and pronociceptive cytokines such as tumour necrosis factor (TNF)-a [2] [3] [4] and neuropathic changes in peripheral neurons [5] . These neuropathic changes are accompanied by behavioural changes indicative of a pathological pain state encompassing allodynia, hyperalgesia and spontaneous pain [5] . Cells in injured and inflamed tissues produce an array of proalgesic lipid metabolites that contribute to a peripheral gating mechanism and thus regulate the access of nociceptive information to the central nervous system [6] . As such, blocking the generation of inflammatory mediators from the oxidative metabolism of arachidonic acid (ARA) with cyclo-oxygenase (COX) inhibitors is commonly used for managing pain in horses, including pain associated with laminitis [1, 7, 8] . However, laminitis pain can be refractory to COX inhibitors and other analgesics [2, 5, 7] , a feature in common with neuropathic pain states [1, 9] .
Cytochrome P450 epoxygenases mediate another critical yet relatively unexplored pathway of ARA and other polyunsaturated fatty acid metabolism by which endogenous bioactive lipids, known as epoxy-fatty acids (EpFAs), are produced [10, 11] . A downstream enzyme, soluble epoxide hydrolase (sEH), metabolises the EpFAs into the corresponding diols [11] [12] [13] [14] [15] . The diols are less active or inactive in terms of antinociception [16] . Extensive evidence in rodent models of inflammatory and neuropathic pain shows that pharmacological inhibition of sEH result in stabilisation of EpFAs and anti nociceptive effects via multiple mechanisms that is significantly greater than COX inhibitors, opioids and gabapentin [9, [17] [18] [19] [20] [21] [22] . In the spinal cord, sEH inhibition result in EpFAs-mediated down-regulation of COX-2 transcription, possibly through a nuclear factorkappa B (NF-jB)-dependent pathway, and rapid up-regulation of the acute neurosteroid-producing gene in the presence of elevated cyclic adenosine monophosphate (cAMP) levels, which then results in neurosteorid production and analgesia via c-aminobutyric acid (GABA) channels [19, 22] . The ARA-derived EpFA 14,15 epoxyeicosatrienoic acid also produces analgesia via activation of b-endorphin and met-enkephalin in the ventrolateral periaqueductal gray (vlPAG) [23] . In peripheral neurons, sEH inhibitors decrease endoplasmic reticulum (ER) stress, resulting in amelioration of neuropathic pain more efficiently than gabapentin [17, 18] . These multiple modes of action are likely to be useful in managing refractory pain in equine laminitis, as suggested in one case report [24] .
Herein, this potential analgesic role is further explored by asking whether sEH activity in the digital laminae of chronic laminitic horses is changed compared with healthy animals, whether sEH inhibitors designed to block human sEH are also able to inhibit the equine sEH, and whether sEH inhibition as adjunct analgesic therapy is associated with changes in forelimb lifts and subjective pain scores in horses with severe chronic laminitis.
Material and methods

Animals
Foundation and an unrelated study evaluating oviductal patency in standing mares [25] . No horses were euthanised for the purpose of the current study. Horses were evaluated for overall health through physical examination, complete blood cell counts and serum biochemical analysis.
Determination of soluble epoxide hydrolase activity in liver and digital laminae Liver samples were collected from the left liver lobe of 4 healthy female intact Quarter horses (3-10 years old) immediately after euthanasia for an unrelated study [25] . Laminar tissues were collected from groups of laminitic (17-19 years old; three male, three female; four Quarter horses, one Paint horse, one Arabian horse) and healthy (2-25 years old; two male, four female; five Quarter horses, one Arabian horse) horses that were being euthanised for reasons unrelated to this study (laminitic horses were euthanised because of chronic laminitis). Horse age does not affect sEH activity in lungs and liver [26] . Immediately after euthanasia, the forefeet were quickly removed by sawing through the first phalanx. Subsequently, starting at the hoof's midline, three sagittal cuts were made 1 cm apart and the laminar tissues from the mid portion of the dorsal region were removed. The tissues were snap-frozen in liquid nitrogen and stored at -80°C until use. Liver samples were homogenised in 15 mL chilled sodium phosphate buffer (20 mmol/L, pH 7.4) containing 5 mmol/L ethylenediaminetetraacetic acid (EDTA), 1 mmol/L dithiothreitol (DTT) and 1 mmol/L phenylmethylsulfonyl fluroid (PMSF). The homogenate was centrifuged at 10,000 g for 20 min at 4°C. The supernatant containing the cytosolic and microsomal fractions (termed S9 fraction) was collected and the pellet (mitochondria/ peroxysome/nucleus fraction) was suspended in 3 mL chilled Tris/HCl buffer (20 mmol/L, pH 8.3) containing 5 mmol/L EDTA. The S9 fraction was again centrifuged at 100,000 g for 60 min at 4°C to separate the cytosolic from the microsomal fractions. As such, after centrifugation, the supernatant was collected and used as the cytosolic fraction, and the pellet was suspended in 3 mL chilled sodium phosphate buffer (10 mmol/L, pH 7.4) containing 5 mmol/L EDTA and 20% glycerol to form the microsomal fraction. The digital laminae samples were homogenised in 5 mL chilled sodium phosphate buffer (20 mmol/L, pH 7.4) containing 5 mmol/L EDTA, 1 mmol/L DTT and 1 mmol/L PMSF. The homogenate was centrifuged at 10,000 g for 20 min at 4°C. The supernatant was used as an S9 fraction (i.e. cytosolic and microsomal fractions combined). All fractions were frozen in liquid nitrogen, and kept at -80°C until use. Protein concentrations were measured with the BCA method using bovine serum albumin as standard. Soluble epoxide hydrolase activity was measured in digital laminae and hepatic tissues using 
Synthesis and potency of soluble epoxide hydrolase inhibitors
The 7 sEH inhibitors used in the current study were synthesised according to procedures described previously [13, 14, [28] [29] [30] . Inhibitory activity of the inhibitors was determined for the equine sEH using the hepatic cytosolic fraction of liver tissue from healthy animals (see above). The cytosol extract was diluted 200-fold in sodium phosphate buffer (0.1 mol/L pH 7.4) containing 0.1 mg/mL BSA. In glass tubes (measurements were done in triplicate), to 100 lL of the protein solution, one microlitre of the inhibitor solution in DMSO ([I] final between 1 and 10,000 nmol/L) was added. The mixture was incubated for 5 min at 30°C before adding one microlitre of a 5 mmol/L solution of [ 3 H]-t-DPPO (8000 cpm/lL; [S] final = 50 lmol/L). The reaction was incubated an additional 10 min at 30°C and then stopped by the addition of 60 lL of methanol. The remaining substrate was extracted with 250 lL of isooctane. The quantity of diol formed was evaluated by measuring the amount of radioactivity present in the aqueous phase using a liquid scintillation counter. The IC 50 , IC 90 and IC 95 values were calculated by nonlinear regression of at least 8 data points using SigmaPlot.
Inhibition of soluble epoxide hydrolase in laminitic horses: physiologic and anti-nociceptive effects
Ten adult horses diagnosed with laminitis and rotation of the third phalanx in relation to the hoof wall of Obel grades 4 (six horses), 3 (three horses) or 2 (one horse), that were not satisfactorily responding to therapy and/or for which euthanasia was being considered were intravenously treated with 0.1 mg/kg bwt t-TUCB every 24 h for a period of 1-10 days. Drug preparation, administration and outcome assessments were performed as described in detail previously [24] . Briefly, t-TUCB was prepared for each individual horse as a 10 mg/mL solution in dimethyl sulfoxide (DMSO) and filter-sterilised prior to use. The horses were evaluated 3-5 times daily starting 1 or 2 days before (baseline) and then during the treatment with t-TUCB. Pain was independently assessed in each horse by at least 2 veterinary professionals (veterinarians and/or veterinary technicians) that were directly involved in patient care with the use of a visual analog scale (VAS; '0' = no pain and '10' = worst possible pain). Forelimb lifts were counted over a 5-min observation period. While assigning pain scores is subjective and can be biased, increased frequency of forelimb lift is an uncharacteristic equine behaviour manifested by laminitic horses that is objectively quantifiable [2, 5] . Increased forelimb lift frequency is indicative of sensory hypersensitivity or a pathologic pain state encompassing allodynia, hyperalgesia and spontaneous pain [5] . Heart rate was assessed with a stethoscope and respiratory rate via direct visualisation of thoracoabdominal movements. Blood pressure was measured with a tail cuff in the standing horse and was not corrected for hydrostatic pressure difference between the heart and the base of the tail. Gastrointestinal sounds were assessed and scored as described previously [2, 24] . Blood was collected for complete blood cell count and serum biochemistry (CBC/ CHEM) before t-TUCB treatment and 24 h after its last dose. Clinically significant behavioural changes or adverse events, which would have led to the discontinuation of the t-TUCB treatment, were recorded.
Data analysis
Statistical analyses were performed with commercially available software (GraphPad Prism version 5.0f for MAC a ). Continuous data were analysed for normality with the D'Agostino & Pearson omnibus or the Shapiro-Wilk normality tests and log-transformed prior to analysis if non-normally distributed. Digital laminae sEH activities were compared between healthy and laminitic horses with unpaired 2-tails t tests. The sEH activities of the different fractions (i.e. cytosol, microsomes and mitochondria/peroxisome/ nucleus) from liver tissue were compared using one-way repeated measures analysis of variance and Bonferroni post-test. Daily outcome measurements of each laminitic horse were averaged to form two sets of data: baseline (1-2 days before t-TUCB dosing) and treatment (1-10 days during t-TUCB dosing) periods. The pain scores and forelimb lifts were also compared between the baseline and the average of responses during the first 3 days of treatment. Continuous baseline and treatment data were compared using paired 2-tails t tests. Noncontinuous data (i.e. gastrointestinal motility scores) were compared using chi-square. A value of P≤0.05 was considered statistically significant. Data are shown as mean AE s.d. unless otherwise indicated.
Results soluble epoxide hydrolase activity in hepatic tissues, digital laminae and soluble epoxide hydrolase inhibition in vitro
In hepatic tissue, sEH activity was significantly higher in the cytosolic fraction (22AE2 nmol/min/mg; P<0.01) than in the microsomal fraction (6.0AE0.5 nmol/min/mg) and in the mitochondria/peroxisome/nuclear fraction (8AE2 nmol/min/mg).
The sEH activity was also measured in the S9 fraction (combined cytosolic and microsomal fractions) of the digital laminae from horses with chronic laminitis as well as from healthy horses. One chronic laminitic horse was classified as Obel grade 0 for lameness severity at the time of euthanasia and was not included in the statistical calculations. Remaining horses were classified as Obel grade 2 (n = 1) or 3 (n = 4). Horses had been diagnosed with laminitis for several years although exact duration was not known. One laminitic horse was being treated with pergolide for pituitary pars intermedia dysfunction, and most (n = 3) were receiving phenylbutazone on an 'as needed' basis (exact dose and schedule not known). Remaining horses had no known systemic co-morbidities. The sEH activity was variable but significantly (P = 0.01) higher in the digital laminae of laminitic horses (0.9AE0.6 nmol/min/mg; 95% CI 0.16-1.55 nmol/min/mg) than of healthy horses (0.17AE0.09 nmol/min/mg; 95% CI 0.07-0.26 nmol/ min/mg). The sEH activity in the one chronic laminitic horse classified as Obel grade 0 at time of euthanasia was 0.09 nmol/min/mg.
Inhibitory activity (IC 50 ) of 7 inhibitors developed against the human sEH and tested previously in animal models was measured against the equine sEH using horse liver cytosol (Table 1) . Based on its potency against the equine sEH, preliminary experience in one laminitic horse [24] , and its previously reported stability in other animals [9, 31] , t-TUCB was selected for further usage. The potency of t-TUCB was further confirmed by its inhibitory activity against the equine sEH in a concentration-response manner (Fig 1) .
Soluble epoxide hydrolase inhibition in vivo
Ten laminitic horses aged 15AE6 years (range 3-24 years), weighing 498AE56 kg (range 408-600 kg) bwt were treated with the sEH inhibitor t-TUCB as an adjunct therapy for an average of 4.3AE3 days (range 1-10 days). Clinical details of the patient cohort are presented in Table 2 . Compared to baseline, addition of t-TUCB to the therapy was associated with a statistically significant decrease of 36AE22% (95% CI 9-64%; P = 0.04) in forelimb lifts (from 5AE1 to 3AE1 lifts/min) and a significant decrease of 18AE23% (95% CI 2-35%; P = 0.04) in pain scores (from 6.8AE2 to 5.5AE2). When the comparison was restricted to the first 3 days of treatment, addition of t-TUCB to therapy was associated with statistically significant decreases of 33AE17% (95% CI 11-54%; P = 0.02) in forelimb lifts and of 14AE15% (95% CI 2-25%; P = 0.03) in pain scores. Figure 2 shows the percent change relative to baseline during the entire treatment period (1-10 days; Fig 2a) or during the first 3 days (Fig 2b) for each horse's pain scores during t-TUCB administration. Horse 1 (*) has been published as a case report [24] . Data from this horse were not included in the statistical calculations.
Compared with baseline, there were no significant changes in respiratory rate (from 19AE5 to 19AE3 breaths/min), heart rate (from 48AE10 to 48AE11 beats/min), mean arterial pressure (from 102AE37 to 97AE28 mmHg) and gastrointestinal motility scores (from 12AE4 to 12AE3) during adjunct therapy with t-TUCB. One horse (Horse 5) developed signs of abdominal pain (i.e. colic) on the second day after starting t-TUCB treatment, t-TUCB was discontinued, and the horse responded promptly to medical treatment. From this horse, two offspring (one male and one female) were born the following year from embryo transfer without any problems. Separately, another horse (horse 3) with unilateral blindness and corneal opacity developed blepharospasm and epiphora (yellow tinge) with evidence of corneal vascularisation after the fourth dose of t-TUCB. There was no evidence of corneal ulceration suggested by lack of fluorescein uptake and treatment with ophthalmic ointment containing oxytetracycline and polymyxin B was instituted. In this horse, t-TUCB was discontinued after the fifth dose due to poor response to treatment and radiographic evidence of septic pedal osteitis and possible pathologic solar margin fractures. The macroscopic ocular changes subsided completely by the fifth day after discontinuing t-TUCB administration. There were no significant changes on physical and laboratory variables with the t-TUCB treatment (Supplementary Items 1 and 2). Severity: The Obel system [49] was used to categorise lameness severity: Grade 1: horses shift weight from one foot to the other or incessantly lift feet. Lameness is not evident at a walk, but at the trot horses will have a shortened stride. Grade 2: horses move willingly at a walk and trot but with a noticeably shortened and stabbing stride. A foot can be lifted off the ground without difficulty. Grade 3: horses move reluctantly and resist attempts to lift affected or contralateral feet. Grade 4: horses express marked reluctance or absolute refusal to move. 
Discussion
The main findings of this study are that sEH activity is significantly increased in digital laminae from laminitic horses compared with healthy horses and adjunct analgesic therapy with t-TUCB, a potent inhibitor of equine sEH, was associated with a statistically significant improvement in forelimb lifts, a pain-associated behaviour of equine laminitis [5] and subjectively assigned pain scores with negligible negative side effects. These results are consistent with reports showing significant decrease in neuropathic and inflammatory pain with sEH inhibitors or EpFAs in rodent models [9, 16, 17, 22] , and confirm earlier observations in one laminitic horse [24] .
The effects of sEH inhibition in laminitis pain likely involve both peripheral and central mechanisms [6, 11] . The findings of increased sEH activity in digital laminae and decrease in pain measures with sEH inhibition in laminitic horses corroborate with a peripheral mechanism of action. It is well recognised that a host of lipid metabolites produced by injured cells in inflamed tissues play a central role in gating peripheral nociception [6] . Peripheral application of EpFAs, especially those derived from the omega-3 fatty acid docosahexaenoic acid (DHA), result in antihyperalgesia [16] . Inhibition of sEH could also decrease the hyperalgesic state in laminitis via modulation of peripheral neuropathy [5] since sEH inhibition significantly ameliorates neuropathic pain via decreasing ER stress in peripheral neurons [17] . A central effect is also possible because sEH inhibitors penetrate the central nervous system where sEH is present and metabolically active [18, 32, 33] and EpFAs can also produce central antihyperalgesia or analgesia [16, 23] . Specific mechanisms include downregulation of COX-2 transcription and up-regulation of neurosteroid synthesis in the spinal cord, up-regulation of endogenous opioid peptides in vlPAG, amelioration of ER stress in peripheral neurons, and downregulation of proinflammatory cytokines [17] [18] [19] 22, 23] . Inhibition of sEH appears to be a mechanistically sound strategy for multimodal pain management in equine laminitis [1, 7] .
Two of the horses studied continued to display refractory pain during sEH inhibitor treatment. There are at least 3 plausible explanations for this finding. First, underlying pain mechanisms could have been sEHindependent. For example, linoleic acid-derived EpFAs in the lipoxigenase pathway can be algogenic via activation of transient receptor potential (TRP) channels [34] . Second, post-translational modifications and polymorphisms of some equine CYP450 epoxygenases [35, 36] could favour the production of EpFA that may not be good sEH substrates thereby being insensitive or poorly sensitive to sEH inhibitors, even if sEH activity is increased. The EpFAs from arachidonic acid can be algogenic or analgesic depending on the experimental conditions [20] , and are less preferred substrates for sEH [16] . Arachidonic acid-derived EpFAs are also involved in angiogenesis [37] [38] [39] and, coincidentally, one of the refractory horses also developed prominent corneal vascularisation. Third, t-TUCB displays a nearbell shaped dose-response curve at a dose range between 0.1 and 100 mg/kg bwt in rodent models of inflammatory and neuropathic pain [9] . If this is also the case in horses, it is possible that the dose of t-TUCB was either too low or too high for these two horses. Current research efforts are being made to elucidate these possibilities and refine therapy.
At present, there are no validated methods for pain assessment in laminitic horses [40] . The VAS used in the present study was considered reliable for assessing lameness in equine laminitis [41] . Reliability tended to be lower for inexperienced observers, but overall reliability was high, especially intrarater reliability [41] . Accordingly, experienced observers used the VAS and the same observers assessed each individual horse during treatment in the current study. Another concern when managing laminitis pain is that pain has a critical adaptive component that if extinguished may lead to further damage to the digital laminae. Pain elimination may also complicate monitoring of disease progression as well as response to treatment [42] . The precise minimum amount of pain required for these adaptive/therapeutic components is difficult to know. The goal of laminitis pain therapy should be to strike the best possible balance in the spectrum spanning from the maladaptive to the adaptive components of pain and thus require an individualised approach. A modest reduction from high pain levels is probably safe provided that other aspects of the disease are being adequately monitored and managed [2, 24, 42, 43 ]. On average, the level of improvement obtained with t-TUCB in the laminitic horses of the current study is consistent with this notion.
No overt adverse effects that could be directly linked to the sEH inhibitor were observed on extensive physical and laboratory examinations. The unexpected corneal vascularisation in one horse that had long-term blindness and corneal opacity prior to enrolment in the study was intriguing but not too surprising. Studies in mice show that EpFAs derived from omega-6 arachidonic acid are proangiogenic [37] whereas EpFAs from the omega-3 fatty acid DHA, the preferred substrates for sEH [16] , are antiangiogenic [39] . These EpFAs also have opposing effects in tumour growth and metastasis formation in mice [37, 39] , a finding that could be relevant in Horses with oncologic disorders. In agreement with findings in other species [19, 22, 28, 31, 44] and in one case report of one horse [24] no signs of central nervous system depression or excitation or motor impairment were observed. The one horse that developed medical colic had other significant risk factors (i.e. Arabian breed, potentially decreased water intake) that could predispose to colic [45] . Exposure to the sEH inhibitor did not prevent the same horse from donating two viable embryos. Apart from Horse 2 who already had gastrointestinal disease and motility problems, there were no significant changes in gastrointestinal motility during t-TUCB treatment in the remaining horses. It is highly unlikely that there would be toxic increases in EpFAs by sEH inhibition since they are endogenously generated, although off-target effects of the sEH inhibitor cannot be completely ruled out. To date, no obvious adverse effects associated with sEH inhibition have been observed in rodents [16, [20] [21] [22] 46] , dogs [28] , nonhuman primates [31] and humans [44] . All but one horse in the present study were being treated with a COX inhibitor. Studies in mice show that sEH inhibitors synergise with COX inhibitors for anti-nociception [46] but antagonise COX inhibitor-induced gastrointestinal ulcer formation [47] . There is no evidence that the current clinically available COX inhibitors directly affect sEH activity.
The relatively small number of horses in the in vivo part of the current study, the lack of blinding and the absence of a control group could be considered limitations of the current study. Without a control group, treatment data was compared with baseline (i.e. before treatment), and hence it is not possible to precisely quantify the relative contribution of sEH inhibition to the changes in forelimb lift frequency and pain scores. It is Per cent change relative to baseline (BL) in individual pain scores during adjunct therapy with 0.1 mg/kg bwt t-TUCB intravenously every 24 h in horses with severe chronic laminitis. Horse 1 (*) has been published as a case report [24] . Panels depict the entire treatment period (a) or the first 3 days of treatment (b).
Equine Veterinary Journal 49 (2017) 345-351 © 2016 EVJ Ltd conceivable that at least some of the changes in forelimb lifts and pain levels could be a manifestation of the normal progression of the condition independent of sEH inhibition. A previous report showed that frequency of forelimb lift and other behavioural changes fluctuates over time even in healthy horses, but laminitic horses consistently display increased forelimb lifts over a 3-day period compared with healthy horses [5] . For this reason, forelimb lift and pain scores were also compared between baseline and the first 3 days of t-TUCB treatment. This comparison was again statistically significant for both outcomes, suggesting that sEH inhibition indeed had a significant contribution to the changes observed. Lack of blinding could have influenced pain scores, which are subjectively assigned, but not limb lifts, which are objectively quantified. The use of DMSO as vehicle and the severity and advanced nature of the condition could be considered additional limitations. It is unlikely that DMSO was a significant confounding factor despite its possible anti-inflammatory and free radical scavenging actions. Its efficacy in the treatment of laminitis is highly questionable [48] , the quantity that each horse received (~500 mg/horse/day) is well below the recommended dose (up to 1600 g/horse/day) [48] and the in vitro experiments showed that DMSO has no sEH inhibitory effects.
In conclusion, sEH activity is significantly increased in horses with active chronic laminitis compared with healthy horses. Several sEH inhibitors initially designed to inhibit the human enzyme are also active against equine sEH. Adjunct therapy with t-TUCB, a potent pharmacological sEH inhibitor, in horses with severe chronic laminitis resulted in mild to moderate, statistically significant, decreases in forelimb lifts and pain scores, suggesting that t-TUCB helped control pathologic pain associated with laminitis [5] . The current results argue for a role of endogenous bioactive lipids in laminitis pain signalling and support further exploration into manipulating these molecules, via sEH inhibition or other strategies, as an additional therapeutic approach for laminitis.
